Business Context and Reporting Period
The filing is The Beauty Health Company’s unaudited Form 10-Q for the quarter and six months ended June 30, 2023. The filing identifies the registrant as The Beauty Health Company, not “Skinhealth Systems Inc.” The company designs, manufactures, markets, and sells aesthetic technologies and products, including Hydrafacial, SkinStylus, and Keravive.
Financial Performance and Position
| Metric | Three Months Ended June 30, 2023 | Three Months Ended June 30, 2022 | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 |
|---|---|---|---|---|
| Net sales | $117.5 million | $103.5 million | $203.8 million | $179.0 million |
| Gross profit | $67.9 million | $70.0 million | $122.0 million | $120.9 million |
| Gross margin | 57.8% | 67.6% | 59.9% | 67.6% |
| Loss from operations | $(13.1) million | $(5.0) million | $(30.5) million | $(19.0) million |
| Net income (loss) | $3.4 million | $6.3 million | $(16.9) million | $37.8 million |
| Net income (loss) per basic share | $0.03 | $0.04 | $(0.13) | $0.25 |
Second-quarter sales increased 13.5%, primarily from Consumables, which rose 33.9% to $51.9 million. Delivery Systems increased 1.2% to $65.6 million. Six-month sales increased 13.9%; Consumables rose 28.0% and Delivery Systems rose 4.2%.
Gross margin declined materially because of higher product costs, unfavorable product mix, increased developed-technology amortization, and, for the six-month period, discontinued and obsolete product charges. Second-quarter selling and marketing expense decreased 4.1% to $43.0 million, while general and administrative expense increased 27.2% to $35.1 million, primarily due to personnel-related compensation, share-based compensation, severance, and restructuring costs.
Six-month net cash provided by operating activities was $9.0 million, compared with cash used of $69.8 million in the prior-year period. Investing cash usage was $24.9 million, including $16.9 million for asset acquisitions. Financing cash usage was $3.7 million. Cash and cash equivalents declined from $568.2 million at December 31, 2022 to $549.7 million at June 30, 2023.
At June 30, 2023, total assets were $1.007 billion, current assets were $767.9 million, and total liabilities were $845.6 million. The company had $736.3 million of net carrying value in 1.25% convertible senior notes due 2026, with $750.0 million principal outstanding. Its $50.0 million revolving credit facility was undrawn, and the company reported compliance with all applicable covenants. Stockholders’ equity was $161.8 million.
Material Changes Versus the Prior Comparable Period
- Revenue grew, but gross margin fell from 67.6% to 57.8% in the quarter and to 59.9% for the six months.
- Operating losses widened to $13.1 million in the quarter and $30.5 million year to date.
- Six-month results shifted from $37.8 million of net income to a $16.9 million net loss. The prior-year result benefited from a $67.2 million warrant-liability fair-value gain, compared with a $2.5 million gain in 2023.
- Interest income increased to $10.0 million for the six months from $0.7 million, primarily because of higher yields on money market investments.
- International Delivery Systems sales increased, while Americas Delivery Systems sales declined against the prior-year Syndeo launch comparison. International Syndeo launches occurred during the second quarter of 2023.
- The company acquired Esthetic Medical, Inc. for $11.8 million in cash and 109,625 shares, and acquired assets from Anacapa Aesthetics LLC. These transactions generated approximately $16.9 million of investing cash outflows and increased intangible assets.
- The company identified and prospectively revised prior-period financial statements for immaterial misstatements involving intercompany eliminations and right-of-return assets. The filing states the misstatements were not material individually or in the aggregate.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management believes available liquidity is sufficient to fund anticipated working capital needs and obligations for at least the next twelve months, but notes that acquisitions, expansion, product launches, and operating conditions could require additional capital.
- The company cites inflation, foreign-exchange movements, higher interest rates, transportation and supply-chain constraints, industry consolidation, competition, and potential renewed pandemic-related disruptions as risks. Pricing actions may reduce demand and may not fully offset cost increases.
- During the third quarter of 2023, the company launched a voluntary initiative to replace certain components in previously manufactured Syndeo systems. The initiative is expected to result in approximately $5 million of expense during the third quarter.
- In July 2023, the company received approximately $5 million under the Employee Retention Credit program. The filing also states that FDA clearance for a SkinStylus acne-scar indication triggered a $1.3 million contingent payment to the seller of Esthetic Medical.
- Hydrafacial has pending litigation against Ageless Serums involving alleged trademark, contract, unfair-competition, and patent claims. The parties reached a tentative settlement, but terms remained under negotiation and required bankruptcy-court approval.
- Hydrafacial is also pursuing patent-infringement claims against Cartessa Aesthetics. Claims involving three patents remained pending, with a trial date not yet set as of the filing.
- The company maintains substantial cash balances that may exceed FDIC insurance limits and warns that a future bank failure could impair liquidity or payments.
- Disclosure controls and procedures were deemed effective as of June 30, 2023. The filing reports no material changes in internal control over financial reporting during the quarter.
Key Facts Investors Should Verify
- Confirm that the intended issuer is The Beauty Health Company, ticker SKIN, rather than the company name supplied in the request.
- Assess whether revenue growth can continue while gross margin remains pressured by product costs, mix, amortization, and obsolete inventory charges.
- Review the $750.0 million convertible notes due 2026 and the company’s ability to fund future debt service and potential conversion-related obligations.
- Evaluate the expected approximately $5 million Syndeo component-replacement expense and any further product-quality or warranty implications.
- Monitor cash burn, acquisition spending, and the company’s stated ability to maintain liquidity without additional debt or equity financing.
- Review the revised prior-period financial statements and determine whether the identified misstatements affect trend analysis or investor confidence in reporting processes.
- Track the Ageless and Cartessa proceedings, including any settlement, court approval, damages, injunctions, or litigation costs.